Detalhe da pesquisa
1.
Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and ß2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD).
Bioorg Med Chem Lett
; 41: 127975, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33753262
2.
CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
J Pharmacol Exp Ther
; 352(3): 559-67, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25576075
3.
Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and ß2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases.
J Med Chem
; 65(15): 10233-10250, 2022 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35901125
4.
Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma.
Bioorg Med Chem Lett
; 19(23): 6565-70, 2009 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19854054
5.
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
J Med Chem
; 60(24): 10026-10046, 2017 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29200281
6.
Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.
J Med Chem
; 57(3): 793-816, 2014 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24400806